Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
DNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.26 - $48.00
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.85M
Market Cap
$421.90M
Enterprise Value$252.33M
Total Cash (Recent Filing)$561.57M
Total Debt (Recent Filing)$438.77M
Price to Earnings (P/E)―
Beta3.27
Next Earnings
May 08, 2025EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.62
Shares Outstanding45,808,500
10 Day Avg. Volume1,272,385
30 Day Avg. Volume1,850,050
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.34
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$9.17Price Target Upside26.13% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Customer EngagementSolid quarter for Cell Engineering led by traction from Biopharma customers.
Restructuring InitiativesSignificant progress made on restructuring initiatives; cost savings run-rate target increased to $250M.
Bears Say
Market ReactionShares are called down more than 10% in after-hours trading as Ginkgo’s 2025 outlook missed expectations.
Revenue GuidanceGinkgo initiated a 2025 revenue guide well below the Street, as the company cited ongoing end market pressures, coupled with some impacts as a result of completing its ~40% workforce reduction.
Revenue PerformanceQ4 miss and light FY25 guidance driven by government contract exposure and slower biotech spending.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.26 and its highest was $48.00 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $421.90M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Feb 25, 2025. The company reported -$2 earnings per share for the quarter, missing the consensus estimate of -$1.504 by -$0.496.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -1.55.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 45,808,500 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$2 in its last earnings report, missing expectations of -$1.504. Following the earnings report the stock price went down -11.467%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
---
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$9.17 (26.13% Upside)
$9.17 (26.13% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 55%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 320.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.05%
12-Months-Change
Fundamentals
Return on Equity
-60.34%
Trailing 12-Months
Asset Growth
-17.29%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
---
DNA Company Deck
---
DNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While the company showcased strong cash management, cost reduction, and growth in Cell Engineering revenue, it faced challenges with declining full-year revenue in Cell Engineering and Biosecurity, as well as uncertainty in government contracts. The successful launch of new tools and services offerings provided a positive outlook, but these were offset by the revenue declines in key segments.Read More>---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$9.17
▲(26.13% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Twist Bioscience
―
Best Analysts Covering DNA
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+53.30%
reiterated a sell rating 29 days ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.30% per trade.
---